Revium Rx.
RVRC evidence brief
What we can confirm
- BioSniper Score:
- 5.4 / 10
- Market Cap:
- $86.8M
- Lead Asset:
- nano-candesartan (Preclinical)
What it means
What to watch
Prepared research question
What matters most for RVRC—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · RVRC
Revium Rx. (RVRC) is a preclinical-stage biotech developing nanoparticle-based reformulations of approved drugs for antibiotic-resistant infections and pancreatic cancer, with $0.8M cash and a $5.5M equity base as of 2026-06-30.
Key risk: Preclinical stage only
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Market Cap
$86.8M
Cash Runway
—
Lead Asset
nano-candesartan (Preclinical)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates for Revium Rx..
Revium Rx. (RVRC) is a preclinical-stage biotech developing nanoparticle-based reformulations of approved drugs for antibiotic-resistant infections and pancreatic cancer, with $0.8M cash and a $5.5M equity base as of 2026-06-30.
- Lead candidate nano-mupirocin targets severe infections from MRSA, VRE, and resistant Neisseria gonorrhoeae using a PEGylated liposomal delivery system [pipeline].
- Second candidate nano-candesartan is a nanoparticle-based angiotensin receptor blocker for pancreatic cancer, partnered with Yissum of the Hebrew University [pipeline].
- Cash & equivalents of $0.8M and shareholders' equity of $5.5M as of 2026-06-30 [sec].
- Net loss of -$0.7M for the period ending 2026-06-30 [sec].
- Both candidates are in preclinical phase, with no disclosed clinical trial data [pipeline].
What works
- Nano-mupirocin addresses a clear unmet need for systemic treatment of antibiotic-resistant bacteria such as MRSA and VRE [pipeline].
- Nano-candesartan leverages a known drug (candesartan) with a novel nanoparticle formulation, potentially reducing development risk [pipeline].
- Partnership with Yissum Research Development Company of the Hebrew University of Jerusalem provides academic collaboration for nano-candesartan [pipeline].
What to weigh
- Both pipeline candidates are at the preclinical stage, with no clinical data or regulatory milestones achieved [pipeline].
- Cash position of $0.8M as of 2026-06-30 is very limited, raising financing risk for ongoing R&D [sec].
- The competitive landscape for pancreatic cancer includes numerous Phase 2/3 trials from larger companies, creating a high bar for nano-candesartan [competitor_trial].
- Net loss of -$0.7M on a small equity base indicates the company is not yet generating revenue [sec].
From the filings
Quoted directly from source documents.
Nano-mupirocin is in preclinical phase for antibiotic-resistant infections.
“Pipeline Candidate: nano-mupirocin Generic Name: mupirocin Indication: severe, life-threatening infections caused by antibiotic-resistant bacteria, including Methicillin-Resistant Staphylococcus aureus (MRSA), Vancomycin-Resistant Enterococci (VRE), and resistant Neisseria gonorrhoeae Phase: Preclinical”
Nano-candesartan is partnered with Yissum for pancreatic cancer.
“Partner: Yissum Research Development Company of the Hebrew University of Jerusalem”
Risks & what to watch (3)›
Key risks
- Preclinical stage only — Both candidates are preclinical with no clinical data, increasing technical and regulatory risk [pipeline].
- Low cash runway — Cash of $0.8M as of 2026-06-30 may be insufficient to advance programs without new financing [sec].
- Intense competition in pancreatic cancer — Multiple Phase 2/3 trials from established players for pancreatic cancer treatments [competitor_trial].
What to watch
- Any initiation of clinical trials for nano-mupirocin or nano-candesartan [pipeline].
- New financing or partnership announcements given the low cash position [sec].
- Competitor progress in pancreatic cancer trials that could affect nano-candesartan's positioning [competitor_trial].
Sources: Competitor trials · Pipeline · Generated October 3, 2026 · How we verify sources →
Run Revium Rx. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Revium Rx. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.29 · 0% dilution
Lead: Preclinical
2 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Financials
Frequently asked questions
What is the AI investment thesis for Revium Rx.?
Revium Rx. (RVRC) is a preclinical-stage biotech developing nanoparticle-based reformulations of approved drugs for antibiotic-resistant infections and pancreatic cancer, with $0.8M cash and a $5.5M equity base as of 2026-06-30.
What is Revium Rx.'s lead drug candidate?
Revium Rx.'s most advanced tracked candidate is nano-candesartan (Preclinical) for pancreatic cancer.
Who is the CEO of Revium Rx.?
Mr. Amir Avraham CPA is the chief executive officer of Revium Rx. (RVRC).
Where is Revium Rx. headquartered?
Revium Rx. (RVRC) is headquartered in Herzliya, Israel.
What therapeutic areas does Revium Rx. focus on?
Revium Rx. develops therapies across Oncology, Infectious Disease.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.